RAPPAPORT ANDREW 4
4 · Olema Pharmaceuticals, Inc. · Filed Jun 23, 2026
Research Summary
AI-generated summary of this filing
Olema (OLMA) Director Andrew Rappaport Receives Stock Option Grant
What Happened Andrew Rappaport, a director of Olema Pharmaceuticals, was granted a derivative award on June 18, 2026 covering 29,500 shares (reported as a stock option) with an exercise/price reported as $0.00. The grant is recorded as an award/acquisition (code A) and has no immediate cash value reported.
Key Details
- Transaction date: 2026-06-18; filing date (Form 4): 2026-06-23 (filed after the typical 2-business-day deadline).
- Securities: 29,500 derivative shares (stock option) at $0.00 per share.
- Shares owned after the transaction: Not disclosed in the supplied filing.
- Vesting: The shares underlying the option vest in 12 equal monthly installments starting June 18, 2026; any unvested portion vests in full on the issuer's next annual meeting if not already vested, subject to continuous service. (See footnote.)
- No indication in the filing that shares were immediately sold, withheld for tax, or part of a 10b5-1 plan.
Context This is a grant of a stock option award to a company director. Such awards are common as compensation and do not necessarily reflect immediate buying or selling sentiment. The grant has a monthly vesting schedule and an acceleration clause tied to the next annual meeting; because it was reported several days after the transaction date, the filing appears to be late relative to the usual two-business-day Form 4 deadline.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-18+29,500→ 29,500 totalExercise: $9.51Exp: 2036-06-18→ Common Stock (29,500 underlying)
Footnotes (1)
- [F1]The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.